Aurora Cannabis (ACB) Stock Price, News & Analysis

Company Overview

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Key Stats

• Today's Range: $4.11 to $4.27
• 50-Day Range: $4.18 to $6.11
• 52-Week Range: $2.84 to $9.35
• Volume: 701,327 shs
• Average Volume: 3.02 million shs
• Market Capitalization: $232.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Aurora Cannabis Stock Analysis - MarketRank™

Aurora Cannabis scored higher than 13% of companies evaluated by MarketBeat, and ranked 923rd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Aurora Cannabis.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aurora Cannabis are expected to decrease in the coming year, from ($0.02) to ($0.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aurora Cannabis is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aurora Cannabis is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aurora Cannabis has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.16% of the float of Aurora Cannabis has been sold short.

Short Interest Ratio / Days to Cover

Aurora Cannabis has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aurora Cannabis has recently increased by 6.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aurora Cannabis does not currently pay a dividend.

Dividend Growth

Aurora Cannabis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.16% of the float of Aurora Cannabis has been sold short.

Short Interest Ratio / Days to Cover

Aurora Cannabis has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aurora Cannabis has recently increased by 6.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.75

News Sentiment

Aurora Cannabis has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Aurora Cannabis this week, compared to 3 articles on an average week.

Search Interest

Only 20 people have searched for ACB on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.

MarketBeat Follows

7 people have added Aurora Cannabis to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aurora Cannabis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of Aurora Cannabis is held by insiders.

Percentage Held by Institutions

47.63% of the stock of Aurora Cannabis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACB Stock Analysis - Frequently Asked Questions

How have ACB shares performed this year?

Aurora Cannabis' stock was trading at $4.7620 on January 1st, 2024. Since then, ACB shares have decreased by 11.0% and is now trading at $4.24.
View the best growth stocks for 2024 here.

How were Aurora Cannabis' earnings last quarter?

Aurora Cannabis Inc. (NASDAQ:ACB) announced its earnings results on Wednesday, May, 12th. The company reported ($8.20) EPS for the quarter, missing analysts' consensus estimates of ($1.70) by $6.50. The company earned $43.56 million during the quarter, compared to analysts' expectations of $55.17 million. Aurora Cannabis had a negative trailing twelve-month return on equity of 2.19% and a negative net margin of 17.47%.

When did Aurora Cannabis' stock split?

Aurora Cannabis shares reverse split on Tuesday, February 20th 2024. The 1-10 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Does Aurora Cannabis have any subsidiaries?

Aurora Cannabis subsidiaries include these companies: Reliva LLC, Whistler Medical Marijuana Corporation, ICC Labs Inc., Anandia Labs Inc, MedReleaf Corp., CanniMed Therapeutics Inc., Larssen Ltd, and others.

Who are Aurora Cannabis' major shareholders?

Top institutional investors of Aurora Cannabis include Parallax Volatility Advisers L.P., Centiva Capital LP (0.08%), Wolverine Trading LLC and Belvedere Trading LLC.

How do I buy shares of Aurora Cannabis?

Shares of ACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aurora Cannabis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurora Cannabis investors own include Canopy Growth (CGC), Cronos Group (CRON), NVIDIA (NVDA), Meta Platforms (META), Humana (HUM), Marinus Pharmaceuticals (MRNS) and American Water Works (AWK).

Company Calendar

• Last Earnings: 5/12/2021
• Today: 11/20/2024
• Next Earnings (Estimated): 2/13/2025
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACB
• Previous Symbol: NYSE:ACB
• CUSIP: N/A
• CIK: 1683541
• Web: auroramj.com
• Phone: (855) 279-4652
• Fax: N/A
• Employees: 1,073
• Year Founded: 2006

Profitability

• EPS (Most Recent Fiscal Year): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-48,620,000.00
• Net Margins: -17.47%
• Pretax Margin: -22.05%
• Return on Equity: -2.19%
• Return on Assets: -1.56%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 3.83
• Quick Ratio: 1.88

Sales & Book Value

• Annual Sales: $200.35 million
• Price / Sales: 1.16
• Cash Flow: $0.23 per share
• Price / Cash Flow: 18.79
• Book Value: $8.18 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 54,840,000
• Free Float: 54,838,000
• Market Cap: $232.52 million
• Optionable: Optionable
• Beta: 1.87